C the Signs
About C the Signs
C the Signs is an AI-powered clinical platform designed to revolutionize early cancer detection. Founded by NHS doctors, the company’s mission is to make early cancer detection a standard for all patients, not a privilege. The platform integrates seamlessly with electronic health records (EHRs) and utilizes artificial intelligence to analyze a wide array of patient data points, including clinical signs, symptoms, risk factors, lifestyle, family history, medical history, drug history, comorbidities, and past test results. This comprehensive analysis allows the system to identify patients at risk of over 100 cancer types, often before a clinician might suspect it, and recommend the most appropriate diagnostic tests or referrals in under 60 seconds.
By proactively identifying high-risk individuals, C the Signs aims to shift healthcare from a reactive to a predictive model, significantly increasing the chances of survival by detecting cancers at their earliest and most curable stages (Stage 1 or 2). The platform has demonstrated impressive results within the UK’s National Health Service (NHS), identifying breast cancer cases years earlier than standard pathways and improving early-stage ovarian cancer diagnoses. Beyond clinical decision support, C the Signs also offers population risk stratification, automated tracking and safety-netting of patients, and real-time dashboards with cancer performance data, contributing to reduced diagnostic delays, improved patient outcomes, and a more equitable and cost-effective cancer care pathway.
What Physicians Need to Know
For physicians, C the Signs offers a tool to make faster, more confident decisions while maintaining clinical autonomy. It provides instant, tailored guidance on next steps, from urgent referrals to diagnostic tests, in under 30-60 seconds. The platform helps identify rare, complex, or vague cancer presentations and recommends personalized investigations or referrals based on national and local guidelines, drawing on over 1,000 validated signs, symptoms, and risk factors. It can reduce unnecessary screenings by ruling out low-risk patients, thereby easing the burden on primary care and healthcare resources. The system also includes real-time dashboards for tracking suspected and confirmed cancer patients, automating safety-netting, and providing performance data. This can lead to a significant increase in cancer detection rates, as demonstrated by a 12.3% increase in one study, without requiring additional staff time.
C the Signs is built with interoperability at its core and seamlessly integrates into electronic health record systems. Specifically, it integrates with NHS electronic medical record systems such as EMIS, SystmOne, and Vision, covering over 97% of primary care EHR systems in the UK. It is FHIR/HL7 compliant. The platform works within existing electronic health records, aiming for no extra clicks and no disruption to workflow.
Reviews & Opinions
Videos
News, demos, and interviews about C the Signs.
Videos load interactively. If none appear, search YouTube for C the Signs →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded C the Signs.
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]
PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]